Navigation Links
Avantra Biosciences Offers Its Proprietary PATH® Slides for Sale

WOBURN, Mass., March 22, 2011 /PRNewswire/ -- Avantra Biosciences has announced they are selling their new and improved proprietary PATH® Protein Microarray Ultra-thin Nitrocellulose Slides. Additionally, Avantra is discussing the possibility of partnering with certain parties to expand the distribution network for the PATH slides.

The PATH Slide is the first protein microarray slide to provide the many benefits of nitrocellulose in a thin film that allows very low background fluorescence and excellent signal-to-noise ratio.

"Nitrocellulose has proven to be the protein-assay substrate of choice for decades. With this technology, researchers can use a wide variety of fluorescence probes to make protein assays easier, faster and more sensitive than ever before," said Brendan McKernan, President of Avantra Biosciences. "By delivering a high signal-to-noise ratio and low background fluorescence, we believe the PATH surface chemistry to be far superior to other commercially available protein-array surfaces."

Key Features:

  • Excellent stability and shelf life

  • Best in class sensitivity, accuracy, and reproducibility and dynamic range providing excellent spot morphology, retained protein conformation and functional activity.

  • Low background and increased dynamic range – proprietary ultra-thin nitrocellulose provides enhances signal-to-noise ratios

  • Standard slide format – adaptable to all commonly used slide format microarray readers

Ordering information
Phone: 877.395.7608
Fax: 617.892.7191

About Avantra Biosciences Corporation

Avantra Biosciences is a privately held diagnostics company that has pioneered next generation technology for protein biomarker analysis.  The PATH technology is integrated into the Avantra Q400 Biomarker Workstation.  Avantra's integrated system enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) from their lab bench or clinical trial site.

Copyright © 2011 Avantra Biosciences Corporation. All rights reserved.

SOURCE Avantra Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
2. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
3. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
4. Swift Biosciences Presents Highly Sensitive, Highly Specific qPCR Mutation Detection Data at 18th International Molecular Medicine Tri-Conference
5. Martek Biosciences Inducted into Small Business Innovation Research (SBIR) Hall of Fame
6. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
7. YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results
8. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
9. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
10. YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
11. Ardea Biosciences Prices Public Offering of Common Stock
Post Your Comments:
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is one ... biomarkers market with pharmaceutical companies and diagnostic ... diagnostic tests. . ... Complete report on global cancer biomarkers market ...
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... , November 25, 2015 ... cat and human plaque and pave the way for more ... problems in cats     --> ... most commonly diagnosed health problems in cats, yet relatively little ... now. Two collaborative studies have been conducted by researchers from ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
Breaking Biology Technology:
(Date:10/26/2015)... Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern authentication ... , today announced the launch of its latest version ... unified platform enabling organizations to use standards-based authentication that ... Nok Nok S3 Authentication Suite is ideal for organizations ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
(Date:10/22/2015)... Mass., Oct. 22, 2015  Aware, Inc. (NASDAQ: AWRE ), ... results for its third quarter ended September 30, 2015.  ... quarter of 2015 was $4.0 million, a decrease of 33% compared ... in the third quarter of 2015 was $2.2 million, or $0.10 ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):